

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re Patent Application of

Norbert MÜLLER

Application No.: 10/624,570

Filed: July 23, 2003

For: METHODS OF SCREENING FOR  
SCHIZOPHRENIA

)  
)  
Group Art Unit: Unassigned  
)  
Examiner: Unassigned  
)  
Confirmation No.: Unassigned  
)  
)

**INFORMATION DISCLOSURE STATEMENT  
TRANSMITTAL LETTER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

No additional fee for submission of an IDS is required.

The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.

A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.

Charge \$ \_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.

A check in the amount of \$ \_\_\_\_\_ is enclosed for the fee due.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: September 18, 2003

By: \_\_\_\_\_  
Teresa Stanek Rea  
Registration No. 30,427

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620



Patent  
Attorney's Docket No. 033285-014

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Patent Application of )  
Norbert MÜLLER ) Group Art Unit: Unassigned  
Application No.: 10/624,570 ) Examiner: Unassigned  
Filed: July 23, 2003 ) Confirmation No.: Unassigned  
For: METHODS OF SCREENING FOR )  
SCHIZOPHRENIA )

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicant hereby submits the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.


The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or statement is required under 37 C.F.R. § 1.97(b).

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.


By:

  
Teresa Stanek Rea  
Registration No. 30,427

Date: September 18, 2003

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Substitute for forms 1449A/PTO & 1449B/PTO		ATTORNEY'S DKT No. 033285-014	APPLICATION NO. 10/624,570
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		APPLICANT Norbert MUELLER	
		FILING DATE July 23, 2003	GROUP 10/624,570



SEP 22 2003

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Tsuang, M.T. et al., <i>Genes, environment and schizophrenia</i> , Br. J. Psychiatry (Suppl.), (2001), 178:40:s18-s24.
	McGue, M. et al., <i>A Single Dominant Gene Still Cannot Account for the Transmission of Schizophrenia</i> , Arch. Gen. Psychiatry, (1989), 46:478-480.
	McGuffin, P. et al., <i>Genetic basis of schizophrenia</i> , The Lancet, (1995), 346:678-682.
	Jurewicz, I. et al., <i>Searching for susceptibility genes in schizophrenia</i> , Eur. Neuropsychopharmacol., (2001), 11:395-398.
	Knapp, M., <i>Schizophrenia costs and treatment cost-effectiveness</i> , Acta. Psychiatr. Scand. (Suppl.), (2000), 407:15-18.
	Ganguli, R. et al., <i>Autoimmunity in Schizophrenia: A Review of Recent Findings</i> , Ann. Med., (1993), 25:489-496.
	Arolt, V. et al., <i>Decreased in vitro production of interferon-gamma and Interleukin-2 in whole blood of patients with schizophrenia during treatment</i> , Mol. Psychiatry, (2000), 5:150-158.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for forms 1449A/PTO & 1449B/PTO		ATTORNEY'S DKT NO. 033285-014	APPLICATION NO. 10/624,570
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		APPLICANT Norbert MUELLER	
		FILING DATE July 23, 2003	GROUP 10/624,570



<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	<i>Schwarz, M.J. et al., Decreased Levels of Soluble Intercellular Adhesion Molecule-1 (sICAM-1) in Unmedicated and Medicated Schizophrenic Patients, Soc. Biol Psychiat., (1999), 47:29-33.</i>		
	<i>Heath, R.G. et al., Antiseptal Brain Antibody in IgG of Schizophrenic Patients, Soc. Biol Psychiatry, (1989), 25:725-733.</i>		
	<i>Sundin, U. et al., Antibody Reactivity to Brain Membrane Proteins in Serum from Schizophrenic Patients, Brain, Behav. Immun., (1989), 3:345-358.</i>		
	<i>Henneberg, A.E. et al., Increased prevalence of antibrain antibodies in the sera from schizophrenic patients, Schizophr. Res., (1994), 14:15-22.</i>		
	<i>Schwarz, M.J. et al., Antibodies to Heat Shock Proteins in Schizophrenic Patients: Implications for the Mechanism of the Disease, Am. J. Psychiatry, (1999), 156:1103-1104.</i>		
	<i>Rothermundt, M. et al., Immunological Dysfunction in Schizophrenia: A Systematic Approach, Neuropsychobiology, (1998), 37:186-193.</i>		
	<i>Schwarz, M.J. et al., T-helper-1 and T-helper-2 Responses in Psychiatric Disorders, Brain, Behav. Immun., (2001), 15:340-370.</i>		
	<i>Torrey, E.F. et al., Could Schizophrenia Be a Viral Zoonosis Transmitted from House Cats?, Schizophr. Bull., (1995), 21:167-171.</i>		
	<i>Lamphear, J.G. et al., Intercellular Adhesion Molecule-1 and Leukocyte Function-Associated Antigen-3 Provide Costimulation for Superantigen-Induced T Lymphocyte Proliferation in the Absence of a Specific Presenting Molecule, J. Immunol., (1998), 160:615-623.</i>		
	<i>Hogg, N. et al., Shape and shift changes related to the function of leukocyte integrins LFA-1 and MAC-1, J. Leukoc. Biol., (2001), 69:893-898.</i>		
	<i>Vora, D.K. et al., Polymorphisms and Linkage Analysis for ICAM-1 and the Selectin Gene Cluster, Genomics, (1994), 21:473-477.</i>		
	<i>Voraberger, G. et al., Cloning of the Human Gene for Intercellular Adhesion Molecule-1 and Analysis of its 5'-Regulatory Region, J. Immunol., (1991), 147:2777-2786.</i>		
	<i>Staunton, D.E. et al., Primary Structure of ICAM-1 Demonstrates Interaction Between Members of the Immunoglobulin and Integrin Supergene Families, Cell (1988), 52:925-933.</i>		
	<i>Jolting, P. et al., Domain 5 of the Intercellular Adhesion Molecule-1 (ICAM-1) Is Involved in Adhesion of B-Cells and Follicular Dendritic Cells, In Vivo Immun., (1994), 355:131-135.</i>		
	<i>Macchioni, P. et al., Intercellular adhesion molecule 1 (ICAM-1) gene polymorphisms in Italian patients with rheumatoid arthritis, Clin. Exp. Rheumatol., (2000), 18:553-558.</i>		
	<i>Boiardi, L. et al., Intercellular Adhesion Molecule-1 Gene Polymorphisms in Behcet's Disease, J. Rheumatol., (2001), 28:1283-1287.</i>		
	<i>Mycko, M. et al., Multiple Sclerosis: The Increased Frequency of the ICAM-1 Exon 6 Gene Point Mutation Genetic Type K469, Am. Neurol. Assn., (1998), 44:70-75.</i>		
	<i>Nishimura, M. et al., Association Between Type 1 Diabetes Age-at-Onset and Intercellular Adhesion Molecule-1 (ICAM-1) Gene Polymorphism, Hum. Immunol., (2000), 61:507-510.</i>		
	<i>Yamaguchi, N. et al., Screening of SLC25A13 Mutations in Early and Late Onset Patients With Citrin Deficiency and in The Japanese Population: Identification of Two Novel Mutations and Establishment of Multiple DNA Diagnosis Methods For Nine Mutations, Hum. Mutat., (2002), 19:122-130.</i>		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for forms 1449A/PTO & 1449B/PTO		ATTORNEY'S DKT NO. 033285-014	APPLICATION NO. 10/624,570
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		APPLICANT Norbert MUELLER	
		FILING DATE July 23, 2003	GROUP 10/624,570



<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	<i>Bocchio, L. et al., Association Between Promoter Polymorphic Haplotypes of Interleukin-10 Gene and Schizophrenia, Soc. Biol. Psychiatry, (2002), 51:480-484.</i>		
	<i>Gately, M.K. et al., The Interleukin-12/Interleukin-12 Receptor System: Role in Normal and Pathologic Immune Responses, Annu. Rev. Immunol., (1998), 16:495-521.</i>		
	<i>Komatsu, T. et al., Interleukin-12 Promotes Recovery from Viral Encephalitis, Viral Immunol., (1997), 10:35-47.</i>		
	<i>Sato, S. et al., Central nervous system cytokine mRNA expression following Theiler's murine encephalomyelitis virus infection, J. Neuroimmunol., (1997), 76:213-223.</i>		
	<i>Wakatsuka, T. et al., A Distinct mRNA Encoding a Soluble Form of ICAM-1 Molecule Expressed in Human Tissues, Cell Adhes. Commun., (1995), 3:283-292.</i>		
	<i>Schwarz, M.J. et al., Decreased Levels of Soluble Intercellular Adhesion Molecule-1 (sICAM-1) in Unmedicated and Medicated Schizophrenic Patients, Soc. Biol. Psychiat., (1999), 47:29-33.</i>		
	<i>Salvarani, C. et al., Intercellular Adhesion Molecule-1 Gene Polymorphisms in Polymyalgia Reumatica/Giant Cell Arteritis: Association with Disease Risk and Severity, J. Rheumatol., (2000), 27:1215-1221.</i>		
	<i>Braun, C. et al., Polymorphisms of the ICAM-1 Gene Are Associated with Inflammatory Bowel Disease, Regardless of the p-ANCA Status, Clin. Immunol., (2001), 101:357-360.</i>		
	<i>Aydintuğ, A.O. et al., Elevated levels of soluble intercellular adhesion molecule-1 correlate with disease activity in Behcet's disease, Rheumatol. Int., (1995), 15:75-78.</i>		
	<i>Coll-Vinent, B. et al., Circulating soluble adhesion molecules in patients with giant cell arteritis. Correlation between soluble intercellular adhesion molecule-1 (sICAM-1) concentrations and disease activity, Ann. Rheum. Dis., (1999), 58:189-192.</i>		
	<i>Göke, M. et al., Elevated serum concentrations of soluble selectin and immunoglobulin type adhesion molecules in patients with inflammatory bowel disease, J. Gastroenterol., (1997), 32:480-486.</i>		
	<i>Littler A.J. et al., A Distinct Profile of Six Soluble Adhesion Molecules (ICAM-1, ICAM-3, VCAM-1, E-Selectin, L-Selectin and P-Selectin) in Rheumatoid Arthritis, Br. Soc. Rheumatol., (1997), 36:164-169.</i>		
	<i>McGue, M. et al., A Single Dominant Gene Still Cannot Account for the Transmission of Schizophrenia, Arch. Gen. Psychiatry, (1989), 46:478-480.</i>		
	<i>McGuffin P. et al., Genetic basis of schizophrenia, The Lancet, (1995) 346:678-682.</i>		
	<i>Rothermundt M. et al., Review of Immunological and Immunopathological Findings in Schizophrenia, Brain, Behav. Immun., (2001) 15:319-339.</i>		
	<i>Printz, D.J. et al., Elevation of CD5<sup>+</sup> B Lymphocytes in Schizophrenia, Soc. Biol. Psychiatry, (1999) 46:110-118.</i>		
	<i>McAllister, C.G. et al., Increased Numbers of CD5<sup>+</sup> B Lymphocytes in Schizophrenic Patients, Arch. Gen. Psychiatry, (1989), 46:890-894.</i>		
	<i>Marenco, S. et al., The neurodevelopmental hypothesis of schizophrenia: Following a trail of evidence from cradle to grave, Dev. Psychopathol., (2000), 12:510-527.</i>		
	<i>Yolken, R.H. et al., Endogenous retroviruses and schizophrenia, Brain Res. Rev., (2000), 31:193-199.</i>		
	<i>Marker, O. et al., Virus-activated T cells regulate expression of adhesion molecules on endothelial cells in sites of infection, J. Neuroimmunol., (1995), 62:35-42.</i>		
	<i>Croft, M. et al., Accessory Molecule and Costimulation Requirements for CD4 T Cell Response, Crit. Rev. Immunol., (1997), 17:89-118.</i>		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for forms 1449A/PTO & 1449B/PTO	ATTORNEY'S DKT NO. 033285-014	APPLICATION NO. 10/624,570
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	APPLICANT Norbert MUELLER	
	FILING DATE July 23, 2003	GROUP 10/624,570



## NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.